Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
$1.99
per week
for 24 weeks
// //

Acceleron Pharma NASDAQ: XLRN-Q

Today's Change
Volume
Delayed Last Update

More stories below advertisement

Latest Press Releases

Merck Completes Acquisition of Acceleron Pharma Inc.
Business Wire - Mon Nov 22, 2021
Business Wire - PRTGAM
Mon Nov 22, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the acquisition of Acceleron Pharma Inc. (Nasdaq: XLRN).
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
Business Wire - Fri Nov 19, 2021
Business Wire - PRTGAM
Fri Nov 19, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, Astros Merger Sub, Inc., for all of the outstanding shares of common stock of Acceleron...
Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer
Business Wire - Wed Nov 17, 2021
Business Wire - PRTGAM
Wed Nov 17, 2021
Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed funds (“Avoro,” “we” or “us”) beneficially owns approximately 7% of...
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
Business Wire - Wed Nov 17, 2021
Business Wire - PRTGAM
Wed Nov 17, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Merck’s pending acquisition of...
Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer
Business Wire - Tue Nov 9, 2021
Business Wire - PRTGAM
Tue Nov 9, 2021
Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed funds (“Avoro,” “we” or "us") beneficially owns approximately 7% of...
Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc.
Business Wire - Mon Nov 8, 2021
Business Wire - PRTGAM
Mon Nov 8, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that its pending acquisition of Acceleron Pharma Inc. (Nasdaq: XLRN) has been cleared by the competition authorities in Germany and Austria.
Acceleron Reports Third Quarter 2021 Financial Results
Business Wire - Thu Nov 4, 2021
Business Wire - PRTGAM
Thu Nov 4, 2021
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today reported financial results for the third...
Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
Business Wire - Fri Oct 29, 2021
Business Wire - PRTGAM
Fri Oct 29, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has withdrawn its Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CXP, XLRN, HRC, DSPG; Shareholders are Encouraged to Contact the Firm
AccessWire - Thu Oct 28, 2021
AccessWire - PRTGAM
Thu Oct 28, 2021
NEW YORK, NY / ACCESSWIRE / October 28, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Columbia Property Trust, Inc. (NYSE:CXP) concerning potential violations of the federal...
Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders
Business Wire - Thu Oct 28, 2021
Business Wire - PRTGAM
Thu Oct 28, 2021
Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, beneficially owns approximately 7% of Acceleron Pharma Inc. (Nasdaq:XLRN) (“Acceleron”, “XLRN” or the “Company”) together with...

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2022.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies